Clinical Trial Update: Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine in resectable pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Adenocarcinoma of the Pancreas
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Resectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas | Phase 2 | Status: COMPLETED